Bardoxolone Methyl对2型糖尿病合并4期慢性肾脏病患者尿白蛋白与肌酐比值的影响
BEACON试验是一项在2185例2型糖尿病合并4期慢性肾脏病患者中进行的3期随机双盲安慰剂对照国际多中心研究。Bardoxolone methyl虽增加eGFR和尿白蛋白与肌酐比值,但早期心衰事件显著增加致试验终止。事后分析显示,bardoxolone methyl组尿白蛋白与肌酐比值的初始升高在6个月后减弱,且以eGFR为索引时白蛋白尿显著减少。
要点
- 在2型糖尿病合并4期CKD患者中,bardoxolone methyl升高eGFR同时伴尿白蛋白与肌酐比值初始增加,但6个月后减弱。
- 基线eGFR和随时间变化的eGFR是与尿白蛋白与肌酐比值变化相关的主要因素。
- 以eGFR为索引时,bardoxolone methyl较安慰剂显著减少白蛋白尿,提示白蛋白尿变化直接与eGFR变化相关。
核心结论
- 在2型糖尿病合并4期慢性肾脏病患者中,bardoxolone methyl治疗引起的白蛋白尿变化与eGFR变化直接相关,挑战了白蛋白尿增加普遍反映肾损伤和危害的传统观念。
研究设计与样本
- BEACON试验为3期安慰剂对照、随机、双盲、平行组、国际多中心试验,纳入2185例2型糖尿病合并4期慢性肾脏病患者。
主要发现
- Bardoxolone methyl导致eGFR和尿白蛋白与肌酐比值升高,但早期心衰事件显著增加致试验终止。
- 随机分配至bardoxolone methyl组的患者中,尿白蛋白与肌酐比值的初始升高在6个月后减弱。
- 多变量回归分析确定基线eGFR和随时间变化的eGFR是与尿白蛋白与肌酐比值变化相关的主要因素。
- 与安慰剂相比,以eGFR为索引时,bardoxolone methyl显著减少白蛋白尿(最小二乘均值:-0.035,95%置信区间-0.031至-0.039)。
关键数值与推荐
- 尿白蛋白与肌酐比值和eGFR在第12周前每4周评估一次,之后每8周评估一次,并在末次给药后4周评估。
- 以eGFR为索引的白蛋白尿变化最小二乘均值差为-0.035(95%置信区间-0.031至-0.039),支持bardoxolone methyl组白蛋白尿显著减少。
临床怎么用
- 对于2型糖尿病合并4期慢性肾脏病患者,bardoxolone methyl引起的白蛋白尿增加可能反映eGFR变化而非肾损伤,临床解读白蛋白尿变化时应结合eGFR动态。
局限性
- 本研究为事后分析,BEACON试验因安全 concerns 提前终止,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bardoxolone methyl attenuates inflammation by inducing nuclear factor erythroid-derived 2-related factor 2 and suppressing nuclear factor κB. The Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) trial was a phase 3 placebo-controlled, randomized, double-blind, parallel-group, international, multicenter trial in 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. BEACON was terminated because of safety concerns, largely related to a significant increase in early heart failure events in patients randomized to bardoxolone methyl. Bardoxolone methyl resulted in increased estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio. Herein, we present post hoc analyses characterizing the relation between the urine albumin-to-creatinine ratio and eGFR. The urine albumin-to-creatinine ratio and eGFR were assessed every four weeks through Week 12, followed by assessments every eight weeks thereafter, and 4 weeks after the last dose of bardoxolone methyl was administered. The initial increases in urine albumin-to-creatinine ratio observed in patients randomized to bardoxolone methyl were attenuated after six months. Multivariable regression analysis identified baseline eGFR and eGFR over time as the dominant factors associated with change in the urine albumin-to-creatinine ratio. Relative to placebo, bardoxolone methyl resulted in a significant decrease in albuminuria when indexed to eGFR (least-squared means: -0.035 [95% confidence interval -0.031 to -0.039]). Thus, among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl, changes in albuminuria are directly related to changes in eGFR, challenging the conventional construct that increases in albuminuria universally reflect kidney injury and denote harm.
引用
- Rossing P, Block GA, Chin MP, et al. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019. PMID: 31377056. doi:10.1016/j.kint.2019.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。